Beta-blockers associated with reduced knee osteoarthritis pain: Study
UK: Commonly used beta-blockers may reduce the cumulative risk for knee pain, knee osteoarthritis (OA), and hip pain consultations, finds a recent study in the journal Rheumatology.
Georgina Nakafero, The University of Nottingham, Nottingham, UK, and colleagues aimed to examine the association between β-blocker prescription and first primary-care consultation for knee osteoarthritis, hip OA, knee pain, and hip pain.
The researchers recruited participants from Clinical Practice Research Datalink and included those aged ≥40 years in receipt of new oral β-blocker prescriptions. They were propensity score (PS) matched to an unexposed control.
Cox proportional hazard ratios (HRs) and 95% confidence intervals (CI) were calculated, and adjusted for non-osteoporotic fractures, number of primary-care consultations for knee or hip injury, and, the number of primary-care consultations, out-patient referrals, and hospitalizations in the 12-months preceding cohort entry. Analysis was stratified according to β-blocker class and for commonly prescribed drugs.
111 718 β-blocker exposed participants were 1:1 PS matched to unexposed controls.
Key findings of the study include:
- β-blocker prescription was associated with reduced cumulative risk of knee OA, knee pain, and hip pain consultations with aHR 0.90; 0.88, and 0.85, respectively.
- Propranolol and atenolol were associated with a lower incidence of knee OA and knee pain consultations with aHRs between 0.78–0.91.
- β-blockers were associated with reduced incidence of consultation for large-joint lower-limb OA/pain as a composite outcome, defined as earliest of knee OA, knee pain, hip OA or hip pain consultation (aHR 0.87).
"Commonly used β-blockers have analgesic properties for musculoskeletal pain," wrote the authors. "Atenolol might be a therapeutic option for OA and cardiovascular co-morbidities in which β-blockers are indicated, while propranolol may be suitable for people with co-morbid anxiety."
"A confirmatory randomized controlled trial is needed before clinical practice is changed," they concluded.
Reference:
The study titled, "β-blocker prescription is associated with lower cumulative risk of knee osteoarthritis and knee pain consultations in primary care: a propensity score matched cohort study," is published in the journal Rheumatology.
DOI: https://academic.oup.com/rheumatology/advance-article/doi/10.1093/rheumatology/keab234/6169013
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.